Dengue virus detection using impedance measured across nanoporous alumina membrane.

Alister En Kai Peh,Sam F. Y. Li

DOI: https://doi.org/10.1016/j.bios.2012.10.054

2013-04-15

Abstract:

What problem does this paper attempt to address?

Dopamine Release from Transplanted Neural Stem Cells in Parkinsonian Rat Striatum in Vivo.

Xinjiang Kang,Huadong Xu,Sasa Teng,Xiaoyu Zhang,Zijun Deng,Li Zhou,Panli Zuo,Bing Liu,Bin Liu,Qihui Wu,Li Wang,Meiqin Hu,Haiqiang Dou,Wei Liu,Feipeng Zhu,Qing Li,Shu Guo,Jingli Gu,Qian Lei,Jing Lu,Yu Mu,Mu Jin,Shirong Wang,Wei Jiang,Kun Liu,Changhe Wang,Wenlin Li,Kang Zhang,Zhuan Zhou

DOI: https://doi.org/10.1073/pnas.1408484111

2014-01-01

Abstract:Embryonic stem cell-based therapies exhibit great potential for the treatment of Parkinson's disease (PD) because they can significantly rescue PD-like behaviors. However, whether the transplanted cells themselves release dopamine in vivo remains elusive. We and others have recently induced human embryonic stem cells into primitive neural stem cells (pNSCs) that are self-renewable for massive/transplantable production and can efficiently differentiate into dopamine-like neurons (pNSC-DAn) in culture. Here, we showed that after the striatal transplantation of pNSC-DAn, (i) pNSC-DAn retained tyrosine hydroxylase expression and reduced PD-like asymmetric rotation; (ii) depolarization-evoked dopamine release and reuptake were significantly rescued in the striatum both in vitro (brain slices) and in vivo, as determined jointly by microdialysis-based HPLC and electrochemical carbon fiber electrodes; and (iii) the rescued dopamine was released directly from the grafted pNSC-DAn (and not from injured original cells). Thus, pNSC-DAn grafts release and reuptake dopamine in the striatum in vivo and alleviate PD symptoms in rats, providing proof-of-concept for human clinical translation.
Detection of autoantibodies against gangliosides in Guillain-Barré syndrome.

Hong-Liang Zhang,Su-Jie Gao,Yi Yang,Jiang Wu

2010-09-01

Abstract:
Co-Transplantation of Gdnf-Overexpressing Neural Stem Cells and Fetal Dopaminergic Neurons Mitigates Motor Symptoms in A Rat Model of Parkinson'S Disease

Xingli Deng,Yuanxin Liang,Hua Lu,Zhiyong Yang,Ru'en Liu,Jinkun Wang,Xiaobin Song,Jiang Long,Yu Li,Deqiang Lei,Zhongtang Feng

DOI: https://doi.org/10.1371/journal.pone.0080880

IF: 3.7

2013-01-01

PLoS ONE

Abstract:Striatal transplantation of dopaminergic (DA) neurons or neural stem cells (NSCs) has been reported to improve the symptoms of Parkinson's disease (PD), but the low rate of cell survival, differentiation, and integration in the host brain limits the therapeutic efficacy. We investigated the therapeutic effects of intracranial co-transplantation of mesencephalic NSCs stably overexpressing human glial-derived neurotrophic factor (GDNF-mNSCs) together with fetal DA neurons in the 6-OHDA rat model of PD. Striatal injection of mNSCs labeled by the contrast enhancer superparamagnetic iron oxide (SPIO) resulted in a hypointense signal in the striatum on T2-weighted magnetic resonance images that lasted for at least 8 weeks post-injection, confirming the long-term survival of injected stem cells in vivo. Co-transplantation of GDNF-mNSCs with fetal DA neurons significantly reduced apomorphine-induced rotation, a behavioral endophenotype of PD, compared to sham-treated controls, rats injected with mNSCs expressing empty vector (control mNSCs) plus fetal DA neurons, or rats injected separately with either control mNSCs, GDNF-mNSCs, or fetal DA neurons. In addition, survival and differentiation of mNSCs into DA neurons was significantly greater following co-transplantation of GDNF-mNSCs plus fetal DA neurons compared to the other treatment groups as indicated by the greater number of cell expressing both the mNSCs lineage tracer enhanced green fluorescent protein (eGFP) and the DA neuron marker tyrosine hydroxylase. The success of cell-based therapies for PD may be greatly improved by co-transplantation of fetal DA neurons with mNSCs genetically modified to overexpress trophic factors such as GDNF that support differentiation into DA cells and their survival in vivo.
Alpha1-adrenergic Receptor mRNA and Inflammatory Mediator Expression in Circulating Leucocytes after Cardiac Surgery

M. Kalkoff,A. Chan-Dominy,J. Sleigh,P. Jogia,R. Cursons,R. Towers,M. La Pine

DOI: https://doi.org/10.1177/0310057X0803600406

2008-07-01

Anaesthesia and Intensive Care

Abstract:Vasodilation after coronary artery bypass surgery is a common complication. Inflammatory mediators influence the expression of alpha 1-adrenergic receptors. Do patients requiring high doses of postoperative inotropic support have down-regulated alpha-adrenergic receptors'? Is there a characteristic pattern of preoperative inflammatory mediator expression that could predict a complicated course after the operation? Forty-four patients undergoing cardiac bypass surgery with extracorporeal circulation were prospectively investigated. Five perioperative blood samples were taken (preoperative, two hours, 12 hours, 36 hours and 72 hours postoperative). The leucocyte mRNA-expression of the three alpha 1-adrenergic receptor subtypes (A, B and D) and 11 different pro-inflammatory mediators were investigated with the real-time reverse transcriptase polymerase chain reaction. The patients were divided into three groups (No-noradrenaline [No-NA]=0 μg/min, Low-noradrenaline [Low-NA]=0.1-7 μg/min, High-noradrenaline [High-NA] >7 ixglmin), according to their postoperative noradrenaline requirements. Preoperatively, alpha 1A-receptor expression was 4.9-fold (High-NA) and 18.7-fold (Low-NA) higher than the No-NA group (P=0.005) and plasma noradrenaline levels were higher in the High-NA group (P=0.005). Across all groups at 12 hours after the operation, alpha 1A-receptor expression decreased to approximately one-fifth of preoperative levels (P=0.01); but with greater duration and magnitude of relative decrease in the High-NA group. Patients in the No-NA group had significant postoperative increases in leucocyte inflammatory mediator expression for IL-1β, TLR4, TREM, MPO, MMP9 and TNF genes, whereas the changes in the Low-NA and High-NA groups were not significant. Low preoperative levels of noradrenaline and low expression of alpha 1A-adrenoreceptors in leucocytes was associated with less probability of requiring noradrenaline support after cardiac surgery.
Dopaminergic progenitors generated by small molecule approach survived, integrated, and promoted functional recovery in (6-OHDA) mouse model of Parkinson's disease

Arshak R Alexanian,Andrey Sorokin,Megan Duersteler

DOI: https://doi.org/10.1016/j.jns.2024.123188

2024-08-20

Abstract:Parkinson's disease (PD) is a neurodegenerative disorder resulting from the loss of dopamine-producing neurons in the brain, causing motor symptoms like tremors and stiffness. Although current treatments like medication and deep brain stimulation can alleviate symptoms, they don't address the root cause of neuron loss. Therefore, cell replacement therapy emerges as a promising treatment strategy. However, the generation of engraftable dopaminergic (DA) cells in clinically relevant quantities is still a challenge. Recent advances in cell reprogramming technologies open up vast possibilities to produce patient-specific cells of a desired type in therapeutic quantities. The main cell reprogramming strategies involve the enforced expression of individual or sets of genes through viral transduction or transfection, or through small molecules, known as the chemical approach, which is a much easier and safer method. In our previous studies, using a small molecule approach (combinations of epigenetic modifiers and SMAD inhibitors such asDorsomorphin and SB431542), we have been able to generate DA progenitors from human mesenchymal stem cells (hMSCs). The aim of this study was to further improve the method for the generation of DA progenitors and to test their therapeutic effect in an animal model of Parkinson's. The results showed that the addition of an autophagy enhancer (AE) to our DA cell induction protocol further increased the yield of DA progenitor cells. The results also showed that DA progenitors transplanted into the mouse model of PD survived, integrated, and improved PD motor symptoms. These data suggest that chemically-produced DA cells can be very promising and safe cellular therapeutics for PD.
Rescue Of Dopamine Release And Behavior By Transplanted Neural Stem Cells In A Rat Model Of Parkinsonism

xinjiang kang,huadong xu,li zhou,panli zuo,zijun deng,bin liu,li wang,haiqian dou,feipeng zhu,changhe wang,shirong wang,wenlin li,kang zhang,zhuan zhou

DOI: https://doi.org/10.1016/j.bpj.2013.11.2922

IF: 3.4

2014-01-01

Biophysical Journal

Abstract:Parkinson's disease (PD) is a neurodegenerative disorder due to reduced dopamine (DA) in the striatum and loss of DA neurons in the substantia nigra pars compacta. Embryonic stem cells (ESCs) are an optimal source for cell therapy for PD. We recently developed a fast (one-week) protocol using small molecules that effectively induces human ESCs to become primitive neural stem cells (pNSCs), which are then differentiated into DA-like neurons in vitro. As pNSCs are infinitely expandable, this approach offers a strategy to readily generate DA neurons on a large scale. But whether these pNSC-differentiated DA (pNSC-DA) neurons can functionally integrate into the damaged brain is unknown. Here, we transplanted pNSC-DA neurons into 6-hydroxydopamine-induced rat models of PD and monitored their behavior for 16 weeks. In striatum in vivo, we first determined that the grafted pNSC-DA neurons secreted DA(using HPLC with a 200-μm microdialysis probe at a sampling rate of 0.002 Hz); then we recorded DA release by electrochemical amperometry (using a 7-μm carbon-fiber electrode at a sampling rate of 1000 Hz), showing that the grafted pNSC-DA neurons significantly rescued DA release in slices (7%) and in vivo (16%). Furthermore, the transplanted cells survived for at least 16 weeks and dramatically rescued the apomorphine-induced asymmetric rotation behavior in PD rats. Thus, we draw the conclusion that transplanted pNSC-DA neurons can functionally integrate into the brain and partially relieve Parkinsonian symptoms in rats. Our work provides direct evidence for a therapeutic role of pNSC-DA neurons in treating Parkinsonian syndrome.
The Effect of Lentivirus-Mediated PSPN Genetic Engineering Bone Marrow Mesenchymal Stem Cells on Parkinson’s Disease Rat Model

Xiaofeng Yin,Huamin Xu,Yunxia Jiang,Wenshuai Deng,Zeyu Wu,Hengwei Xiang,Peng Sun,Junxia Xie

DOI: https://doi.org/10.1371/journal.pone.0105118

IF: 3.7

2014-08-13

PLoS ONE

Abstract:Persephin (PSPN) is one of the neurotrophic factors of the glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) which have been found to promote the survival of specific populations of neurons. The aim of this study was to assess the potential therapeutic function of gene-modified mesenchymal stem cells (MSCs)-Lv-PSPN-MSCs in 6-OHDA-induced Parkinson's disease (PD) rats models. Here, we worked on the isolation, purification, identification and amplification of MSCs in vitro. The expression analysis revealed that several of the neural marker proteins like nestin, GFAP and S100 were expressed by rat MSCs. MES23.5 cells co-cultured with Lv-PSPN-MSCs showed less 6-OHDA induced cell death than control cells in vitro. When Lv-PSPN-MSCs were injected into the striatum of PD rats, we observed the survival rate, migration, differentiation and the behavior change of PD rats. We found that Lv-PSPN-MSCs showed higher survival rate in rat brain compared with Lv-null-MSCs. Rotational behavior showed that rats receiving Lv-PSPN-MSCs showed the most significant improvement compared with those in other groups. HPLC results showed the content of DA in striatum of rats which received Lv-PSPN-MSCs was highest compared with those in other groups. In conclusion, our results suggest that transplantation of Lv-PSPN-MSCs can lead to remarkable therapeutic effects in PD rats.

multidisciplinary sciences
Mortality of dialysis patients according to influenza and pneumococcal vaccination status.

T. Bond,A. Spaulding,J. Krisher,W. McClellan

DOI: https://doi.org/10.1053/j.ajkd.2012.04.018

IF: 11.072

2012-12-01

American Journal of Kidney Diseases

Abstract:BACKGROUND Data from an immunocompromised subpopulation in which both vaccine recipients and nonrecipients have frequent opportunities for vaccination can help determine the associations between vaccination against seasonal influenza and pneumococcal disease and all-cause mortality. STUDY DESIGN We surveyed dialysis centers and performed a retrospective analysis of health status at dialysis therapy initiation, vaccination for influenza and pneumococcal disease, laboratory results, and mortality associated with the 2005-2006 influenza season for patients in 3 End-Stage Renal Disease Networks across the United States. SETTING & PARTICIPANTS Of 1,033 dialysis facilities considered, 903 centers with a total patient population of 54,734 reported vaccination data. Analysis was limited to 36,966 patients on dialysis treatment for at least 1 year as of December 31, 2005. PREDICTOR Vaccination status. OUTCOMES OR for all-cause mortality (vaccinated vs unvaccinated patients). RESULTS The estimated adjusted OR for mortality was significantly less than 1.0 for patient who received either vaccination and was lower for patients who had received both vaccinations than for those who had received either. Survival analysis confirmed these findings. LIMITATIONS Possible misclassification due to self-report of vaccination for some patients. Lack of vaccination date. CONCLUSIONS Vaccination against influenza and pneumococcal disease is associated with improved survival in dialysis patients. The 2 vaccinations have independent effects on mortality.
Chemical Conversion of Mouse Fibroblasts into Functional Dopaminergic Neurons

Yonghui Wang,Hao Yang,Qiong Yang,Junhua Yang,Hao Wang,Huiming Xu,Wei-Qiang Gao

DOI: https://doi.org/10.1016/j.yexcr.2016.07.026

IF: 4.145

2016-01-01

Experimental Cell Research

Abstract:Ectopic expression of lineage-specific transcription factors facilitates the conversion of mammalian somatic cells into dopaminergic (DA) neurons, which is a promising strategy for cell therapy of Parkinson's disease (PD). However, this approach still has some drawbacks limiting its clinical application due to the potential risks of integrating vectors into the host genome. Therefore, it is critical to seek a more desired approach to generate DA neurons derived from mammalian somatic cells. Here, we report that mouse embryonic fibroblasts (MEFs) can be efficiently converted into DA neurons by using small molecules along with specific growth factors. These neuron-like cells generate DA neuronal morphology, and acquire immunocytochemical and calcium imaging special for neuronal electrophysiological profile. More importantly, these converted cells can secrete dopamine, indicating that they are functionally similar to DA neurons. Taken together, our study might provide a promising cell source for treating PD by using chemical approach without introduction of exogenous transcription factors.
Modern chromatographic procedures in systematic toxicological analysis.

R. A. de Zeeuw

DOI: https://doi.org/10.1016/s0378-4347(00)82946-1

IF: 4.601

Journal of Chromatography A

Abstract:
[Postpartum thrombotic thrombocytopenic purpura in a pregnant woman with hypertension].

E. González-Bosquet,N. Pages,M. Borrás,J. Lailla

Abstract:
Therapeutic effects of intranigral transplantation of mesenchymal stem cells in rat models of Parkinson's disease

Dandan Chen,Wenyu Fu,Wenxin Zhuang,Cui Lv,Fengjie Li,Xin Wang

DOI: https://doi.org/10.1002/jnr.23879

Abstract:Stem cell transplantation is a promising tool for the treatment of neurodegenerative disorders, including Parkinson's disease (PD); however, the therapeutic routes and mechanisms of mechanical approaches to stem cell transplantation must be explored. This study tests the therapeutic effect of transplantation of rat bone marrow mesenchymal stem cells (MSCs) into the substantia nigra (SN) of the PD rat. 5-Bromo-2-deoxyuridine-labeled rat MSCs were transplanted into the SN of the 6-hydroxydopamine-injected side of PD rat brains. The behavioral changes in PD rats were examined before and 4 and 8 weeks after MSC transplantation. The expression of tyrosine hydroxylase (TH) in the SN and the striatum and the survival and differentiation of MSCs were assessed by immunohistochemical and double immunofluorescence techniques. Abnormal behavior of PD rats was significantly improved by the administration of bone marrow MSCs, and the number of TH-positive cells in the SN and the optical density of TH-positive fibers in the striatum were markedly increased. Transplanted MSCs can survive and migrate in the brain and differentiate into nestin-, neuron-specific enolase-, and GFAP-positive cells. Our findings suggest that transplantation of rat bone marrow MSCs into the SN of PD rats may provide therapeutic effects. © 2016 Wiley Periodicals, Inc.
Cone ERGs to Flash Trains: The Antagonism of a Later Flash

M. Saeki,P. Gouras

DOI: https://doi.org/10.1016/0042-6989(96)00024-7

IF: 1.8

1996-10-01

Vision Research

Abstract:
Research progress of neural stem cells as a source of dopaminergic neurons for cell therapy in Parkinson's disease

Lingling Zhang,Hao Yang

DOI: https://doi.org/10.1007/s11033-024-09294-y

IF: 2.7422

2024-02-25

Molecular Biology Reports

Abstract:Parkinson's disease (PD) is a neurodegenerative disease, the most characteristic pathological feature is the progressive loss of dopaminergic (DA) neurons in the substantia nigra pars compactus (SNpc) of the mesencephalon, along with reduced dopamine content in the striatum. Researchers have been searching for drugs and therapies to treat PD in decades. However, no approach could stop the progression of the disease, and even some of them caused adverse clinical side effects. PD has a well-defined lesion. Therefore, it is considered to be one of the most curable central nervous system diseases by cell replacement treatment. Fetal ventral mesencephalic tissue transplantation has been used to treat patients with PD and obtained positive treatment results. However, ethical issues, such as limited donor tissue, and side effects including graft-induced dyskinesias, limit its clinical applications. Neural stem cell (NSC) transplantation is a viable therapy choice because it possesses multipotency, self-renewal ability, and differentiation into DA neurons, which may substitute for lost DA neurons and slow down the neurodegenerative process in PD. Studies that investigated the delivery of NSCs by using animal models of PD revealed survival, migration, and even amelioration of behavioral deficits. Here, the research progress of NSCs or NSC-derived DA neurons in treating PD was reviewed, and the practicability of present manufacturing processes for clinical testing was considered. This review is expected to offer ideas for practical strategies to solve the present technical and biological problems related to the clinical application of NSCs in PD.

biochemistry & molecular biology
Nano‐Enabled Intracellular Bursting of Calcium and Retinoic Acid Regulates Dopaminergic Neuronal Differentiation of NSCs for Parkinson's Disease Therapy

Shuo Zhang,Qi Liu,Wenjuan Zhou,Tiantian Zhao,Jiapei Shi,Na Ren,Jingang Wang,Fengjuan Shan,Hongli Wang,Jie Wang,Chunhui Sun,Zenan Wang,Aijun Hao,Hong Liu,Shuping Wang

DOI: https://doi.org/10.1002/adfm.202406797

IF: 19

2024-08-03

Advanced Functional Materials

Abstract:A new method is proposed to regulate dopaminergic neuronal differentiation of neural stem cells (NSCs) through nano‐enabled intracellular bursting of calcium ions and retinoic acid. Calcium ions act as accelerators, promoting differentiation, while retinoic acid guides differentiation toward dopaminergic neurons. The transplanted NSCs with endocytosed calcium‐retinoic acid (Ca‐RA) nanoparticles can achieve dopaminergic differentiation in vivo and improve motor and memory abilities of parkinson's disease (PD) mice. Parkinson's disease (PD) is a debilitating neurodegenerative disorder characterized by dopaminergic neuron degeneration. Neural stem cell (NSC) therapy offers promise for replacing these neurons and restoring neural function. However, directing NSCs to become dopaminergic neurons is challenging. Retinoic acid (RA) is a potential regulator, but its insolubility in water limits its use in PD therapy. Herein, nanonizing RA with calcium acetate to create calcium‐retinoic acid nanoparticles (Ca‐RA NPs) is proposed. These nanoparticles can be internalized by NSCs and then dissociated in the acidic environment of lysosomes to lead to a burst of Ca2+ and RA. In vitro results showed that the intracellular bursting of Ca2+ and RA accelerated neuronal differentiation and maturation by 5–10 days compared to spontaneous NSC differentiation. Importantly, Ca‐RA NPs uniquely directed NSCs to dopaminergic neurons, involving the interaction between the calcium ion‐mediated MAPK signaling pathway and the RA‐mediated RA signaling pathway. Animal experiments further validated the efficacy of Ca‐RA‐coated NSCs in restoring motor and cognitive functions in PD mice by rapidly forming dopaminergic neural circuits. Given that both RA and calcium acetate are approved by the FDA, this strategy has the potential for translation into a clinical treatment approach for stem cell therapy of PD.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
Human Autologous Ipsc-Derived Dopaminergic Progenitors Restore Motor Function in Parkinson's Disease Models.

Bin Song,Young Cha,Sanghyeok Ko,Jeha Jeon,Nayeon Lee,Hyemyung Seo,Kyung-Joon Park,In-Hee Lee,Claudia Lopes,Melissa Feitosa,Maria Jose Luna,Jin Hyuk Jung,Jisun Kim,Dabin Hwang,Bruce M. Cohen,Martin H. Teicher,Pierre Leblanc,Bob S. Carter,Jeffrey H. Kordower,Vadim Y. Bolshakov,Sek Won Kong,Jeffrey S. Schweitzer,Kwang-Soo Kim

DOI: https://doi.org/10.1172/jci130767

2020-01-01

Abstract:Parkinson's disease (PD) is a neurodegenerative disorder associated with loss of striatal dopamine, secondary to degeneration of midbrain dopamine (mDA) neurons in the substantia nigra, rendering cell transplantation a promising therapeutic strategy. To establish human induced pluripotent stem cell-based (hiPSC-based) autologous cell therapy, we report a platform of core techniques for the production of mDA progenitors as a safe and effective therapeutic product. First, by combining metabolism-regulating microRNAs with reprogramming factors, we developed a method to more efficiently generate clinical-grade iPSCs, as evidenced by genomic integrity and unbiased pluripotent potential. Second, we established a "spotting"-based in vitro differentiation methodology to generate functional and healthy mDA cells in a scalable manner. Third, we developed a chemical method that safely eliminates undifferentiated cells from the final product. Dopaminergic cells thus express high levels of characteristic mDA markers, produce and secrete dopamine, and exhibit electrophysiological features typical of mDA cells. Transplantation of these cells into rodent models of PD robustly restores motor function and reinnervates host brain, while showing no evidence of tumor formation or redistribution of the implanted cells. We propose that this platform is suitable for the successful implementation of human personalized autologous cell therapy for PD.
Preclinical Comparison of Stem Cells Secretome and Levodopa Application in a 6-Hydroxydopamine Rat Model of Parkinson's Disease

Fábio G Teixeira,Helena Vilaça-Faria,Ana V Domingues,Jonas Campos,António J Salgado

DOI: https://doi.org/10.3390/cells9020315

IF: 6

2020-01-28

Cells

Abstract:Parkinson's Disease (PD) is characterized by the massive loss of dopaminergic neurons, leading to the appearance of several motor impairments. Current pharmacological treatments, such as the use of levodopa, are yet unable to cure the disease. Therefore, there is a need for novel strategies, particularly those that can combine in an integrated manner neuroprotection and neuroregeneration properties. In vitro and in vivo models have recently revealed that the secretome of mesenchymal stem cells (MSCs) holds a promising potential for treating PD, given its effects on neural survival, proliferation, differentiation. In the present study, we aimed to access the impact of human bone marrow MSCs (hBM-MSCs) secretome in 6-hydroxydopamine (6-OHDA) PD model when compared to levodopa administration, by addressing animals' motor performance, and substantia nigra (SN), and striatum (STR) histological parameters by tyrosine hydroxylase (TH) expression. Results revealed that hBM-MSCs secretome per se appears to be a modulator of the dopaminergic system, enhancing TH-positive cells expression (e.g., dopaminergic neurons) and terminals both in the SN and STR when compared to the untreated group 6-OHDA. Such finding was positively correlated with a significant amelioration of the motor outcomes of 6-OHDA PD animals (assessed by the staircase test). Thus, the present findings support hBM-MSCs secretome administration as a potential therapeutic tool in treating PD, and although we suggest candidate molecules (Trx1, SEMA7A, UCHL1, PEDF, BDNF, Clusterin, SDF-1, CypA, CypB, Cys C, VEGF, DJ-1, Gal-1, GDNF, CDH2, IL-6, HSP27, PRDX1, UBE3A, MMP-2, and GDN) and possible mechanisms of hBM-MSCs secretome-mediated effects, further detailed studies are needed to carefully and clearly define which players may be responsible for its therapeutic actions. By doing so, it will be reasonable to presume that potential treatments that can, per se, or in combination modulate or slow PD may lead to a rational design of new therapeutic or adjuvant strategies for its functional modeling and repair.
Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate.

T. Matsumoto,H. Miyazaki,Y. Nakahashi,J. Hirohara,T. Seki,Kyoichi Inoue,K. Okazaki

DOI: https://doi.org/10.1016/J.HEPRES.2004.08.015

2004-11-01

Hepatology Research

Abstract:
Human iPSC-derived midbrain organoids functionally integrate into striatum circuits and restore motor function in a mouse model of Parkinson's disease

Xin Zheng,Deqiang Han,Weihua Liu,Xueyao Wang,Na Pan,Yuping Wang,Zhiguo Chen

DOI: https://doi.org/10.7150/thno.80271

IF: 11.6

2023-01-01

Theranostics

Abstract:Rationale: Parkinson's disease (PD) is a prevalent neurodegenerative disorder that is characterized by degeneration of dopaminergic neurons (DA) at the substantia nigra pas compacta (SNpc). Cell therapy has been proposed as a potential treatment option for PD, with the aim of replenishing the lost DA neurons and restoring motor function. Fetal ventral mesencephalon tissues (fVM) and stem cell-derived DA precursors cultured in 2-dimentional (2-D) culture conditions have shown promising therapeutic outcomes in animal models and clinical trials. Recently, human induced pluripotent stem cells (hiPSC)-derived human midbrain organoids (hMOs) cultured in 3-dimentional (3-D) culture conditions have emerged as a novel source of graft that combines the strengths of fVM tissues and 2-D DA cells. Methods: 3-D hMOs were induced from three distinct hiPSC lines. hMOs at various stages of differentiation were transplanted as tissue pieces into the striatum of naïve immunodeficient mouse brains, with the aim of identifying the most suitable stage of hMOs for cellular therapy. The hMOs at Day 15 were determined to be the most appropriate stage and were transplanted into a PD mouse model to assess cell survival, differentiation, and axonal innervation in vivo. Behavioral tests were conducted to evaluate functional restoration following hMO treatment and to compare the therapeutic effects between 2-D and 3-D cultures. Rabies virus were introduced to identify the host presynaptic input onto the transplanted cells. Results: hMOs showed a relatively homogeneous cell composition, mostly consisting of dopaminergic cells of midbrain lineage. Analysis conducted 12 weeks post-transplantation of day 15 hMOs revealed that 14.11% of the engrafted cells expressed TH+ and over 90% of these cells were co-labeled with GIRK2+, indicating the survival and maturation of A9 mDA neurons in the striatum of PD mice. Transplantation of hMOs led to a reversal of motor function and establishment of bidirectional connections with natural brain target regions, without any incidence of tumor formation or graft overgrowth. Conclusion: The findings of this study highlight the potential of hMOs as safe and efficacious donor graft sources for cell therapy to treat PD.

medicine, research & experimental
Dopaminergic precursors differentiated from human blood-derived induced neural stem cells improve symptoms of a mouse Parkinson's disease model

Yanpeng Yuan,Xihe Tang,Yun-Fei Bai,Shuyan Wang,Jing An,Yanchuan Wu,Zhi-Qing David Xu,Y. Alex Zhang,Zhiguo Chen

DOI: https://doi.org/10.7150/thno.26643

IF: 11.6

2018-01-01

Theranostics

Abstract:Autologous neural stem cells (NSCs) may offer a promising source for deriving dopaminergic (DA) cells for treatment of Parkinson's disease (PD). Methods: By using Sendai virus, human peripheral blood mononuclear cells (PBMNCs) were reprogrammed to induced NSCs (iNSCs), which were then differentiated to dopaminergic neurons in vitro. Whole-genome deep sequencing was performed to search for mutations that had accumulated during the reprogramming and expansion processes. To find the optimal differentiation stage of cells for transplantation, DA precursors obtained at various differentiation time points were tested by engraftment into brains of naïve immunodeficient mice. At last, the safety and efficacy of iNSC-derived DA precursors were tested by transplantation into the striatum of immunodeficient PD mouse models. Results: PBMNC-derived iNSCs showed similar characteristics to fetal NSCs, and were able to specifically differentiate to DA neurons with high efficiency in vitro. The sequencing data proved that no harmful SNVs, Indels and CNVs were generated during the reprogramming and expansion processes. DA precursors obtained between differentiation day 10 to 13 in vitro were most suitable for transplantation when a balanced graft survival and maturation were taken into account. Two weeks after transplantation of DA precursors into mouse PD models, the motor functions of PD mice started to improve, and continued to improve until the end of the experiments. No graft overgrowth or tumor was observed, and a significant number of A9-specific midbrain DA neurons were surviving in the striatum. Conclusion: This study confirmed the efficacy of iNSC-derived DA precursors in a mouse PD model, and emphasized the necessity of genomic sequencing and vigorous safety assessment before any clinical translation using iNSCs.

medicine, research & experimental

Dengue virus detection using impedance measured across nanoporous alumina membrane.

Dopamine Release from Transplanted Neural Stem Cells in Parkinsonian Rat Striatum in Vivo.

Detection of autoantibodies against gangliosides in Guillain-Barré syndrome.

Co-Transplantation of Gdnf-Overexpressing Neural Stem Cells and Fetal Dopaminergic Neurons Mitigates Motor Symptoms in A Rat Model of Parkinson'S Disease

Alpha1-adrenergic Receptor mRNA and Inflammatory Mediator Expression in Circulating Leucocytes after Cardiac Surgery

Dopaminergic progenitors generated by small molecule approach survived, integrated, and promoted functional recovery in (6-OHDA) mouse model of Parkinson's disease

Rescue Of Dopamine Release And Behavior By Transplanted Neural Stem Cells In A Rat Model Of Parkinsonism

The Effect of Lentivirus-Mediated PSPN Genetic Engineering Bone Marrow Mesenchymal Stem Cells on Parkinson’s Disease Rat Model

Mortality of dialysis patients according to influenza and pneumococcal vaccination status.

Chemical Conversion of Mouse Fibroblasts into Functional Dopaminergic Neurons

Modern chromatographic procedures in systematic toxicological analysis.

[Postpartum thrombotic thrombocytopenic purpura in a pregnant woman with hypertension].

Therapeutic effects of intranigral transplantation of mesenchymal stem cells in rat models of Parkinson's disease

Cone ERGs to Flash Trains: The Antagonism of a Later Flash

Research progress of neural stem cells as a source of dopaminergic neurons for cell therapy in Parkinson's disease

Nano‐Enabled Intracellular Bursting of Calcium and Retinoic Acid Regulates Dopaminergic Neuronal Differentiation of NSCs for Parkinson's Disease Therapy

Human Autologous Ipsc-Derived Dopaminergic Progenitors Restore Motor Function in Parkinson's Disease Models.

Preclinical Comparison of Stem Cells Secretome and Levodopa Application in a 6-Hydroxydopamine Rat Model of Parkinson's Disease

Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate.

Human iPSC-derived midbrain organoids functionally integrate into striatum circuits and restore motor function in a mouse model of Parkinson's disease

Dopaminergic precursors differentiated from human blood-derived induced neural stem cells improve symptoms of a mouse Parkinson's disease model